Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Horst Schran"'
Publikováno v:
European Journal of Clinical Pharmacology
Purpose The study aimed to characterize the population pharmacokinetics of panobinostat, a pan-deacetylase inhibitor that has demonstrated efficacy in combination with bortezomib and dexamethasone in patients with multiple myeloma. Methods A nonlinea
Autor:
Xiaofeng Wang, Oezlem Anak, Wei Zhou, Eric Angevin, Bernard Escudier, Horst Schran, Margaret Dugan, Yilin Feng, Andrea Kay
Publikováno v:
The Journal of Clinical Pharmacology. 53:14-20
Dovitinib is an oral multitargeted kinase inhibitor with potent activity against receptors for vascular endothelial growth factor, platelet-derived growth factor, and basic fibroblast growth factor. Initial phase 1 to 2 studies of dovitinib using a c
Autor:
James B. Mangold, Chiaki Tanaka, X. Hong, Yancy Du, Mark J. McKeage, Jimmy Flarakos, Horst Schran, P.C. Fong
Publikováno v:
Cancer Chemotherapy and Pharmacology. 69:1145-1154
Purpose To determine the mass balance, excretion and metabolism of the small molecule flavonoid tumour vascular disrupting agent ASA404 in patients with advanced cancer.
Autor:
Horst Schran, Joseph M. Custodio, Ophelia Q. P. Yin, Arun Krishna, Wei Zhou, Ivana Galetic, Jeiry Filian, Marc Rudoltz, Georg Golor
Publikováno v:
The Journal of Clinical Pharmacology. 51:1580-1586
Nilotinib, a potent orally bioavailable BCR-ABL tyrosine kinase inhibitor, is currently available as a hard gelatin capsule that must be swallowed whole. For patients who may have difficulty swallowing the intact capsule, an alternative mode of admin
Autor:
Michael Hayes, Dong-Wook Kim, Yu Jin, Horst Schran, Eren Demirhan, Sa-Hee Park, Yanfeng Wang, Eugene Y. Tan
Publikováno v:
British Journal of Clinical Pharmacology. 71:199-206
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Imatinib mesylate, a tyrosine kinase inhibitor, exhibits a weak competitive inhibition on paracetamol (acetaminophen) O-glucuronidation with an inhibition constant (Ki) value of 59 µm. However, the clinic
Publikováno v:
The Journal of Clinical Pharmacology. 50:960-967
7053 Background: Nilotinib, a highly selective and potent BCR-ABL tyrosine kinase inhibitor, is approved for the treatment of CML-CP and CML-AP patients resistant or intolerant to prior therapy including imatinib. The solubility of nilotinib is pH de
Autor:
Horst Schran, Thomas M. Smith, K. Grouss, Venkat Sethuraman, Hagop M. Kantarjian, X Wang, Francis J. Giles, Chiaki Tanaka, Ophelia Q. P. Yin, Lawrence Galitz, Oliver G. Ottmann
Publikováno v:
Clinical Pharmacology & Therapeutics. 87:197-203
This article describes studies that investigated the pharmacokinetics of nilotinib, a highly specific, oral, second-generation BCR-ABL tyrosine kinase inhibitor. After a once- or twice-daily regimen at doses ranging from 50 to 1,200 mg/day in 119 pat
Autor:
Francois-Xavier Mahon, Yen Lin Chia, Jerry Nedelman, Horst Schran, Yanfeng Wang, Mathieu Molimard
Publikováno v:
Therapeutic Drug Monitoring. 31:579-584
Background Correlation analyses have demonstrated that maintaining an adequate imatinib (IM) trough concentration would be important for clinical response in patients with chronic myeloid leukemia (CML) and Kit-positive gastrointestinal stromal tumor
Autor:
Neil Gallagher, Chiaki Tanaka, Douglas M. Heuman, Ophelia Q. P. Yin, Deirdre Fisher, Venkat Sethuraman, Horst Schran, Tsu-Han Lin, Wei Zhou
Publikováno v:
Clinical Therapeutics. 31:2459-2469
Background: Nilotinib is a second-generation BCR-ABL tyrosine kinase inhibitor approved for the treatment of patients who have imatinib-resistant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic or accelerated phase or who are
Publikováno v:
The Journal of Clinical Pharmacology. 48:763-775
Midostaurin is a novel potent inhibitor of both protein kinase C and the major receptor for vascular endothelial growth factor involved in angiogenesis, presenting a rationale for its use in diabetic retinopathy. This study evaluated the safety and p